OSE Immuno: new communications in sight















(Boursier.com) — OSE Immunotherapeutics SA presents new scientific advances through an oral presentation and selected posters at international conferences: at the 37th annual meeting of the SITC (Society for Immunotherapy of Cancer) in Boston from November 8 to 12 and at the 14th annual meeting Protein & Antibody Engineering Summit (PEGS) Europe in Barcelona from 14 to 16 November.

These communications highlight the latest preclinical data from our innovative Myeloid and BiCKI research platforms, and in particular OSE-230 (first pro-resolving monoclonal antibody) in chronic inflammation, CLEC-1 (new myeloid immune checkpoint ) and BiCKI-IL-7 (new bifunctional therapy targeting PD-1 and IL-7) in immuno-oncology.

“We are very proud to share with the international scientific community the latest scientific advances from our innovative research platforms, the aim of which is to develop next-generation first-in-class immunotherapies”, comments Nicolas Poirier, CEO of OSE Immunotherapeutics. . Aurore Morello, Director of Research at OSE Immunotherapeutics, continues: “These communications underline the potential therapeutic value of our 3 actives at the advanced preclinical stage. BiCKI-IL-7, our bispecific anti-PD1/IL-7 program presents an approach innovative ‘cytokine’ by selectively targeting specific antitumor T cells to improve the quality and durability of T lymphocyte memory responses. CLEC-1 is our new myeloid checkpoint, continuing our work on the SIRP?/CD47 axis OSE-230 is the first pro-resolving agonist monoclonal antibody capable of eliminating chronic neutrophil infiltrates and blocking the pathogenic process of NETosis and fibrosis.”


©2022 Boursier.com






Source link -87